Cargando empresa
Keep exploring
The themes Generate Biomedicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B US$A+
EXELExelixis, Inc.16,8B US$A+
JAZZJazz Pharmaceuticals plc15,5B US$A
TECHBIO-Techne Corp11,4B US$A+
HALOHalozyme Therapeutics, Inc.11,4B US$A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now A
Cómo gana dinero
- Research collaboration payments100 %
Los porcentajes de ingresos son estimaciones para six months ended June 30, 2026, no cifras de un informe oficial.
Qué vende3
GB-0895
An experimental antibody that blocks thymic stromal lymphopoietin, an immune-system signal. It is being tested in late-stage trials for severe asthma.
GB-4362
An experimental medicine designed to neutralize monomethyl auristatin E, a drug used in some cancer treatments. It has entered human testing.
GB-5267
An experimental cancer treatment using modified chimeric antigen receptor T cells, immune cells altered to recognize and attack cancer. It is being developed with Roswell Park Comprehensive Cancer Center.
Quién se lo compra2
- Amgen, which pays for research under a collaboration agreement.
- Novartis, which pays for research under a collaboration agreement.
En qué se apoya y qué podría romperlo
De qué depende el negocio
- 1Current revenue depends on research work under agreements with Amgen and Novartis; the company says the work under both agreements is nearing completion.
- 2Clinical research and manufacturing rely in part on outside providers, including contract research organizations and contract development and manufacturing organizations.
- 3Developing and selling medicines depends on clinical trials and regulatory approval.
Qué podría salir mal
- 1GB-0895 and the other experimental medicines may not prove safe and effective in clinical trials or receive regulatory approval.
- 2The company has no medicine sales, and its current collaboration revenue depends on research agreements whose work is nearing completion.
- 3The company has ongoing operating losses and expects to need additional funding to continue research and clinical development; it may not obtain that funding on acceptable terms or at all.
Estados financieros completos →
Sobre Generate Biomedicines, Inc.
Generate Biomedicines uses artificial intelligence and laboratory experiments to design and test proteins that could become medicines. Its most advanced candidate is being tested in severe asthma, and it is also developing treatments for other diseases. It has no medicines approved for sale; its current revenue comes from research collaborations with drug companies.
- Sede
- Cambridge, Massachusetts
- Fundada en
- 2018
- Cotiza en
- NASDAQ
- Cierre del ejercicio
- December 31
Construido a partir de los propios informes de Generate Biomedicines, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
